AU2020274319B2 - Small molecule modulators of gut bacterial bile acid metabolism - Google Patents

Small molecule modulators of gut bacterial bile acid metabolism

Info

Publication number
AU2020274319B2
AU2020274319B2 AU2020274319A AU2020274319A AU2020274319B2 AU 2020274319 B2 AU2020274319 B2 AU 2020274319B2 AU 2020274319 A AU2020274319 A AU 2020274319A AU 2020274319 A AU2020274319 A AU 2020274319A AU 2020274319 B2 AU2020274319 B2 AU 2020274319B2
Authority
AU
Australia
Prior art keywords
disease
cancer
compound
substituted
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020274319A
Other languages
English (en)
Other versions
AU2020274319A1 (en
Inventor
Arijit ADHIKARI
Abigail Sloan Devlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of AU2020274319A1 publication Critical patent/AU2020274319A1/en
Application granted granted Critical
Publication of AU2020274319B2 publication Critical patent/AU2020274319B2/en
Priority to AU2026203554A priority Critical patent/AU2026203554A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2020274319A 2019-05-10 2020-05-08 Small molecule modulators of gut bacterial bile acid metabolism Active AU2020274319B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026203554A AU2026203554A1 (en) 2019-05-10 2026-05-09 Small molecule modulators of gut bacterial bile acid metabolism

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962846457P 2019-05-10 2019-05-10
US62/846,457 2019-05-10
US202062962048P 2020-01-16 2020-01-16
US62/962,048 2020-01-16
PCT/US2020/032016 WO2020231776A1 (en) 2019-05-10 2020-05-08 Small molecule modulators of gut bacterial bile acid metabolism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026203554A Division AU2026203554A1 (en) 2019-05-10 2026-05-09 Small molecule modulators of gut bacterial bile acid metabolism

Publications (2)

Publication Number Publication Date
AU2020274319A1 AU2020274319A1 (en) 2021-12-02
AU2020274319B2 true AU2020274319B2 (en) 2026-02-12

Family

ID=73289482

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020274319A Active AU2020274319B2 (en) 2019-05-10 2020-05-08 Small molecule modulators of gut bacterial bile acid metabolism
AU2026203554A Pending AU2026203554A1 (en) 2019-05-10 2026-05-09 Small molecule modulators of gut bacterial bile acid metabolism

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026203554A Pending AU2026203554A1 (en) 2019-05-10 2026-05-09 Small molecule modulators of gut bacterial bile acid metabolism

Country Status (8)

Country Link
US (1) US12577273B2 (enExample)
EP (1) EP3965748A4 (enExample)
JP (2) JP7769176B2 (enExample)
KR (2) KR102893599B1 (enExample)
CN (2) CN120757601A (enExample)
AU (2) AU2020274319B2 (enExample)
BR (1) BR112021022431A2 (enExample)
WO (1) WO2020231776A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
WO2020117945A1 (en) 2018-12-04 2020-06-11 President And Fellows Of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
IT202200008861A1 (it) * 2022-05-03 2023-11-03 Chemelectiva S R L Processo per la preparazione di derivati dell’acido colico.
CN115337312B (zh) * 2022-08-19 2025-06-03 金熊药业(珠海横琴)有限公司 胆酸复合物及其制备方法和应用
CN117801047B (zh) * 2023-01-19 2024-12-20 北京华睿鼎信科技有限公司 神经甾体衍生物及其用途
CN118021751A (zh) * 2024-01-15 2024-05-14 中国人民解放军总医院第五医学中心 一种免疫调节的口服微球、制备方法及应用
US20250299939A1 (en) * 2024-03-25 2025-09-25 Thermo Finnigan Llc Calibration of an Image Current-based Mass Analyzer Included in a Mass Spectrometer
WO2025235593A1 (en) * 2024-05-09 2025-11-13 The Regents Of The University Of California Treatment for obstructive sleep apnea-associated atherosclerosis
CN119565571B (zh) * 2024-10-17 2025-11-21 湖北省食品质量安全监督检验研究院(湖北食品、保健食品、化妆品质量安全检测中心) 一种不溶性吸附除氟复合材料颗粒及其制备方法、应用和除氟包
CN119950519B (zh) * 2025-01-07 2025-11-21 山东省海洋科学研究院(青岛国家海洋科学研究中心) 奥贝胆酸在对虾急性肝胰腺坏死病防治中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508453A (en) * 1993-05-20 1996-04-16 Sanofi Intermediate for use in the preparation of taurocholanic acids
WO2017142895A1 (en) * 2016-02-15 2017-08-24 Regents Of The University Of Minnesota Compositions and methods for treating clostridium associated diseases
WO2019075365A1 (en) * 2017-10-13 2019-04-18 Battelle Memorial Institute PROBE FOR BSH (BILE SALT HYDROLASE), ITS PREPARATION AND USE METHOD

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1360354A (en) 1972-01-20 1974-07-17 Union International Co Ltd Chenodeoxycholic acid
JPS5826360B2 (ja) 1974-08-23 1983-06-02 エ−ザイ カブシキガイシヤ グリコケノデオキシコ−ルサンノ セイホウ
IT1221734B (it) 1983-02-24 1990-07-12 Schiena Michele Giuseppe Di Ursodesossicolico solfato acido sale sodico
US5210272A (en) 1990-02-16 1993-05-11 Prototek, Inc. Process for forming a fluoromethyl ketone
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
NZ245504A (en) 1991-12-20 1995-08-28 Hoechst Ag Bile acid derivatives containing an ethylenically unsaturated grouping
IT1255450B (it) 1992-06-30 1995-10-31 Montefarmaco Spa Uso di acidi biliari come agenti antivirali
EP0624593A3 (de) 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
CN1132586C (zh) 1993-09-09 2003-12-31 罗拉斯医疗公司 来自胆汁的免疫调节组合物、其制备方法及其用途
US5695738A (en) 1995-06-15 1997-12-09 Glycomed Incorporated Steroidal C-glycosides
US5763435A (en) 1995-11-21 1998-06-09 Children's Hospital Medical Center Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders
CA2206047A1 (en) 1997-05-23 1998-11-23 Romeo Rang (Deceased) Immunomodulating compositions for the treatment of viral disorders
DE19849722A1 (de) 1998-10-28 2000-05-04 Aventis Pharma Gmbh Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JP2002543216A (ja) 1999-04-30 2002-12-17 アーチ ディベロップメント コーポレイション ステロイド誘導体
DE19941764A1 (de) 1999-09-02 2001-03-15 Aventis Pharma Gmbh Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente
WO2001021642A1 (de) 1999-09-22 2001-03-29 Aventis Pharma Deutschland Gmbh 4-benzylaminochinoline konjugaten mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung
US6451355B1 (en) 2000-07-17 2002-09-17 Howard M. Reisner Composition to treat diabetes
ITTO20020102A1 (it) 2002-02-06 2003-08-06 Abc Ist Biolog Chem Spa Procedimento per la preparazione dell'acido ursodesossicolico disolfato e suoi sali farmaceuticamente accettabili.
ITMI20030822A1 (it) 2003-04-18 2004-10-19 Erregierre Spa Processo per la preparazione dell'acido ursodesossicolico
US20070032464A1 (en) 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
UA90718C2 (ru) 2005-05-10 2010-05-25 Лаборатуар Фурнье С.А. Новое применение агонистов печеночного рецептора х
US9295677B2 (en) 2008-02-26 2016-03-29 Qing Bile Therapeutics Inc. Polyhydroxylated bile acids for treatment of biliary disorders
US8771668B2 (en) 2008-04-09 2014-07-08 Cornell University Commensal bacteria as signal mediators within a mammalian host
US8318663B2 (en) 2008-11-26 2012-11-27 Satiogen Pharmaceuticals, Inc. Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
IT1393095B1 (it) 2009-02-19 2012-04-11 Prodotti Chimici Alimentari Processo per la sintesi del sale disodico dell'acido ursodesossicolico 3,7-disolfato.
JP2013500986A (ja) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓ｘ受容体アゴニスト
CN102712672B (zh) 2009-08-25 2016-09-14 胆清医药有限公司 用于治疗胆疾病的多羟基化胆汁酸
KR20140030171A (ko) 2011-05-02 2014-03-11 바이오키어 인코포레이티드 당뇨병 치료를 위한 조성물 및 치료법
JP2015506349A (ja) 2011-12-21 2015-03-02 アルデリックス， インコーポレイテッド 非全身性ｔｇｒ５アゴニスト
WO2013113680A1 (en) 2012-02-03 2013-08-08 Aarhus Universitet Radiolabeled bile acids and bile acid derivatives
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
US9580459B2 (en) 2013-04-26 2017-02-28 Metselex, Inc. Water-soluble ursodeoxycholic acid prodrugs
ES2748692T3 (es) 2014-11-19 2020-03-17 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides
WO2016100619A2 (en) 2014-12-17 2016-06-23 Rgenix, Inc. Treatment and diagnosis of cancer
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
TW201704251A (zh) * 2015-04-29 2017-02-01 正大天晴藥業集團股份有限公司 鵝去氧膽酸衍生物
TW201700447A (zh) 2015-06-19 2017-01-01 英特賽普醫藥品公司 Tgr5調控劑及其用法
TWI618714B (zh) 2015-08-27 2018-03-21 中央研究院 涎酸轉移酶抑制劑及其用途
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US20170233431A1 (en) * 2016-02-17 2017-08-17 City Of Hope Bile acid derivatives and methods for synthesis and use
RU2665685C1 (ru) 2017-09-18 2018-09-04 Общество с ограниченной ответственностью "МДК Медика" Способ получения алкиламмонийных солей алкилсерных кислот
WO2019191637A1 (en) 2018-03-29 2019-10-03 Metselex, Inc. Compositions for the prevention and treatment of parkinson's disease
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
WO2020117945A1 (en) 2018-12-04 2020-06-11 President And Fellows Of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
WO2021226447A1 (en) 2020-05-08 2021-11-11 President And Fellows Of Harvard College Methods for inducing bile acid sulfotransferase sult2a for treating metabolic disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508453A (en) * 1993-05-20 1996-04-16 Sanofi Intermediate for use in the preparation of taurocholanic acids
WO2017142895A1 (en) * 2016-02-15 2017-08-24 Regents Of The University Of Minnesota Compositions and methods for treating clostridium associated diseases
WO2019075365A1 (en) * 2017-10-13 2019-04-18 Battelle Memorial Institute PROBE FOR BSH (BILE SALT HYDROLASE), ITS PREPARATION AND USE METHOD

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE Pubchem 13 September 2017 (2017-09-13), ANONYMOUS: "Ethyl pregnanecarboxylate", XP055762144, retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/129820655 *
FRIED A A ET AL: "The synthesis of diazo, halo, and sulfoxy bile acid derivatives: Potential affinity labels", STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 34, no. 2, 1 August 1979 (1979-08-01), pages 171 - 187. *
Kurosawa, T., Nakano, H., Sato, M. and Tohma, M., 1995. Synthesis of 3α, 7α, 12α-trihydroxy-and 3α, 7α-dihydroxy-5β-cholestan-26-oic acids by the use of β-ketosulfoxide. Steroids, 60(7), pp.439-444. *
Kurosawa, T., Sato, M., Nakano, H. and Tohma, M., 1996. Synthesis of diastereomers of 3α, 7α, 12α, 24-tetrahydroxy-and 3α, 7α, 24-trihydroxy-5β-cholestan-26-oic acids and their structures. Steroids, 61(7), pp.421-428. *
National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 68236652. Retrieved December 4, 2024 from https://pubchem.ncbi.nlm.nih.gov/compound/68236652. Date created: November 30, 2012 (Year: 2012) *

Also Published As

Publication number Publication date
BR112021022431A2 (pt) 2022-05-24
CN120757601A (zh) 2025-10-10
KR20250171471A (ko) 2025-12-08
EP3965748A1 (en) 2022-03-16
JP2026000925A (ja) 2026-01-06
CN114641280A (zh) 2022-06-17
JP7769176B2 (ja) 2025-11-13
CA3137308A1 (en) 2020-11-19
EP3965748A4 (en) 2023-02-01
CN114641280B (zh) 2025-05-27
KR20220007112A (ko) 2022-01-18
KR102893599B1 (ko) 2025-12-01
AU2020274319A1 (en) 2021-12-02
WO2020231776A8 (en) 2021-05-14
WO2020231776A1 (en) 2020-11-19
US12577273B2 (en) 2026-03-17
AU2026203554A1 (en) 2026-05-28
US20220204548A1 (en) 2022-06-30
JP2022533069A (ja) 2022-07-21

Similar Documents

Publication Publication Date Title
US12577273B2 (en) Small molecule modulators of gut bacterial bile acid metabolism
AU2021218228B2 (en) Oxysterols and methods of use thereof
ES2973500T3 (es) Compuesto de isoxazol como agonista de FXR y composiciones farmacéuticas que lo comprenden
CA3005760C (en) Compounds and methods for inhibiting production of trimethylamine
US12103946B2 (en) Steroid compounds as Treg modulators and uses thereof
AU2018258355A1 (en) Modulators of sestrin-gator2 interaction and uses thereof
WO2022029438A1 (en) Alpha,beta unsaturated methacrylic esters with anti-inflammatory properties
EP3890745B1 (en) Synthetic derivatives of cholic acid 7-sulfate and uses thereof
EP2504000A1 (en) Transcription factor inhibitors and related compositions, formulations and methods
CN112805279A (zh) 异噁唑衍生物及其制备方法和用途
BR112019017003A2 (pt) antibióticos macrocíclicos de amplo espectro
CA2946609A1 (en) Naphthaquinone methyltransferase inhibitors and uses thereof
US10961231B2 (en) NTCP inhibitors
JP2020500907A (ja) 細胞外クエン酸の取込みの阻害剤としてのスルホンアミド
BR122025012723A2 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, respectivos usos, método para inibir hidrolase do sal biliar (bsh) e kit
US20240239738A1 (en) (S)-3-AMINO-4-(DIFLUOROMETHYLENE)CYCLOHEXENE AND CYCLOHEXANE CARBOXYLIC ACID AND USES THEREOF AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE (hOAT)
US20260076966A1 (en) Method of inhibiting trem-1
WO2025165846A1 (en) Rhodoquinone mimetics and methods of making and using thereof
TW201544494A (zh) 胰高血糖素樣肽第一型（ｇｌｐ－１）受體調控子及其於調節血糖濃度之用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)